Telehealth Weight Loss Drugs: A Risky Prescription?

Telehealth companies are increasingly offering weight loss medications, leading to a rise in patient adverse events. One patient experienced a severe overdose within 24 hours of her first dose, requiring hospitalization and causing lingering health issues. This incident underscores worries that some online providers may not adequately screen patients or provide proper follow-up care for GLP-1 medications.

The demand for these drugs has surged, with many telehealth services simplifying the prescription process. This ease of access, however, has attracted criticism. Medical experts express concern that virtual evaluations might be insufficient for identifying potential risks like pancreatitis or thyroid cancer, leading to medication errors and dangerous side effects.

Data indicates a dramatic increase in medication errors related to popular weight loss drugs, with reports skyrocketing from over 2,000 in 2020 to over 25,000 in 2025. Furthermore, there has been a nearly 1,500% increase in poison control calls concerning these medications since 2019. The unregulated nature of compounded versions of these drugs, often sourced internationally, adds another layer of risk.

Legal challenges are also emerging, with pharmaceutical giants suing telehealth companies for promoting compounded drugs. These lawsuits allege deceptive practices and risks to patient safety. Regulatory bodies have issued warning letters to various online companies for making misleading claims about compounded weight loss medications.